Tahereh Damghani

Alıntı yapanlar

	Hepsi	2019 yılından bugüne
Alıntılar	181	152
h-endeksi	9	7
i10-endeksi	8	5

201420152016201720182019202020212022202320241 1 5 11 9 4 12 24 27 63 22

Genel erişim

Tümünü görüntüle

5 makale

1 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Somayeh PirhadiUniversity of Pittsburghpitt.edu üzerinde doğrulanmış e-posta adresine sahip
Najmeh EdrakiAssociate Professor of Medicinal Chemistry, Shiraz University of Medical Sciencessums.ac.ir üzerinde doğrulanmış e-posta adresine sahip
Omidreza FiruziProfessor of Pharmacology, Director MNCRC, Shiraz University of Medical Sciencessums.ac.ir üzerinde doğrulanmış e-posta adresine sahip
Fatemeh MoosaviAssistant Professor of Pharmacology, Shiraz University of Medical Sciencessums.ac.ir üzerinde doğrulanmış e-posta adresine sahip
Mehdi KhoshneviszadehAssociate professor of Medicinal chemistry, Shiraz University of Medical Sciencessums.ac.ir üzerinde doğrulanmış e-posta adresine sahip
Issa YavariUniversity of Tarbiat Modaresmodares.ac.ir üzerinde doğrulanmış e-posta adresine sahip
David HeppnerJ. Solo Assistant Professor of Medicinal Chemistry, The State University of New York at Buffalobuffalo.edu üzerinde doğrulanmış e-posta adresine sahip

Takip et

Tahereh Damghani

University at Buffalo, The State University of New York

buffalo.edu üzerinde doğrulanmış e-posta adresine sahip

medicinal chemistry cancer research structure-based drug design kinase inhibitors


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met T Damghani, F Moosavi, M Khoshneviszadeh, M Mortazavi, S Pirhadi, ... Scientific Reports 11 (1), 3644, 2021	25	2021
Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes T Damghani, T Sedghamiz, S Sharifi, S Pirhadi Journal of Molecular Structure 1203, 127456, 2020	23	2020
Copper-catalyzed S-arylation of tetramethylguanidine–heterocumulene adducts I Yavari, M Nematpour, T Damghani Tetrahedron Letters 55 (7), 1323-1325, 2014	18	2014
Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3, 4-dihydropyrimidin-2 (1H)-one C5 amide derivatives F Moosavi, A Ebadi, M Mohabbati, T Damghani, M Mortazavi, R Miri, ... European Journal of Pharmacology, 173850, 2021	16	2021
N-sulfonyl ketenimine as a versatile intermediate for the synthesis of heteroatom containing compounds S Bahadorikhalili, M Divar, T Damghani, F Moeini, S Ghassamipour, ... Journal of Organometallic Chemistry 939, 121773, 2021	15	2021
Sulfonoketenimides as key intermediates for the synthesis of 2-thioxo-2-1,3-thiazines and 2-arylimino-2-1,3-thiazines I Yavari, M Nematpour, T Damghani Molecular diversity 17 (4), 801-808, 2013	13	2013
Design, synthesis, in vitro evaluation and molecular docking study of N'-Arylidene imidazo [1, 2-a] pyridine-2-carbohydrazide derivatives as novel tyrosinase inhibitors T Damghani, S Hadaegh, S Pirhadi, R Sabet, M Khoshneviszadeh, ... Journal of Molecular Structure 1222, 128876, 2020	12	2020
Copper-Catalyzed One-Pot Synthesis of N-Sulfonylalkanimidoyl Thiocyanates from Sulfonyl Azides, Alkynes, and KSCN. I Yavari, T Damghani, M Nematpour Helvetica Chimica Acta 96 (12), 2013	12	2013
Dual potent c-Met and ALK inhibitors: from common feature pharmacophore modeling to structure based virtual screening S Pirhadi, T Damghani, MS Avestan, S Sharifi Journal of Receptors and Signal Transduction 40 (4), 357-364, 2020	9	2020
Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition Tahereh Damghani, Maryam Elyasi, Somayeh Pirhadi, Haghighijoo Zahra, Somayeh ... Molecular Diversity, 2021	7*	2021
In silico screening of c-Met tyrosine kinase inhibitors targeting nucleotide and drug-substrate binding sites of ABCB1 as potential MDR reversal agents F Moosavi, T Damghani, S Ghazi, S Pirhadi Journal of Receptors and Signal Transduction 42 (6), 549-561, 2022	4	2022
Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors O Mortazavi, Motahareh Divar, Masoumeh Damghani, Tahereh Moosavi, Fatemeh ... Frontiers in Chemistry, 1381, 2022	4*	2022
Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study K Mashayekh, S Sharifi, T Damghani, M Elyasi, MS Avestan, S Pirhadi Combinatorial chemistry & high throughput screening 22 (9), 635-648, 2019	4	2019
Prediction of cytotoxic activity of a series of 1H-pyrrolo [2, 3-b] pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints T Damghani, K Mashayekh, S Pirhadi, O Firuzi, S Sharifi, N Edraki, ... Journal of Receptors and Signal Transduction 39 (4), 295-303, 2019	4	2019
Benzyl‐Triazole Derivatives of Hydrazinecarbothiamide Derivatives as Potent Tyrosinase Inhibitors: Synthesis, Biological Evaluation, Structure‐Activity Relationship and Docking … M Divar, S Tadayyon, M Khoshneviszadeh, S Pirhadi, M Attarroshan, ... ChemistrySelect 8 (8), e202203382, 2023	3	2023
Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors. T Damghani, F Wittlinger, TS Beyett, MJ Eck, SA Laufer, DE Heppner	3	2023
Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design. F Wittlinger, BC Ogboo, CD Pham, IK Schaeffner, SP Chitnis, T Damghani, ...	3	2023
Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors M Divar, N Edraki, T Damghani, F Moosavi, M Mohabbati, A Alipour, ... Bioorganic & Medicinal Chemistry 90, 117367, 2023	2	2023
Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library OF Motahareh Mortazavi, Elaheh Raufi, Tahereh Damghani, Mehdy ... European Journal of Pharmacology, 2022	2*	2022
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors F Wittlinger, BC Ogboo, E Shevchenko, T Damghani, CD Pham, ... Communications Chemistry 7 (1), 38, 2024	1	2024

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar